Crossmark

Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018–2020

Crossref DOI link: https://doi.org/10.1186/s40545-023-00559-8

Published Online: 2024-03-11

Published Print: 2023-12-31

Update policy: https://doi.org/10.1080/tandf_crossmark_01

Authors

Khazanchi, Rohan http://orcid.org/0000-0003-2230-0517
Powers, Samuel

Killelea, Amy

Strumpf, Andrew

Horn, Tim

Hamp, Auntré

McManus, Kathleen A. http://orcid.org/0000-0001-5786-0018
Funding

Funding for this research was provided by:

National Institute of Allergy and Infectious Diseases (K08AI136644)

Grants for Emerging Researcher Mentorship
License Information

Version of Record valid from 2023-12-31
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=jppp20

Publication History

Received: 2022-11-30

Accepted: 2023-04-04

Published: 2024-03-11